Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanc

    Cancer Categories
    • Lung
    Karmanos Trial ID
    • 2020-094
    NCT ID
    • NCT04077463
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    PRIMARY OBJECTIVES:
    • To confirm the tolerability of RP2D of lazertinib (Phase 1)
    • To determine the tolerability and identify the recommended Phase 2 combination dose (RP2CD) of lazertinib when combined with JNJ-61186372 (Phase 1b combination cohorts)
    • To characterize the safety and tolerability of lazertinib and JNJ-61186372 combinations at the RP2CD in participants with advanced NSCLC with documented EGFR mutation (Phase 1b expansion cohorts)
    • To estimate the antitumor activity of lazertinib and JNJ-61186372 combinations at the RP2CD in participants with advanced NSCLC with documented EGFR mutation (Phase 1b expansion cohorts)

    SECONDARY OBJECTIVES:
    • To characterize the safety of lazertinib as a monotherapy (Phase 1) or in combination with JNJ-61186372 (Phase 1b combination cohorts)
    • To characterize the PK of lazertinib as a monotherapy (Phase 1) or in combination with JNJ-61186372 (Phase 1b)
    • To characterize the PK and immunogenicity of JNJ-61186372 in combination with lazertinib (Phase 1b)
    • To assess additional measures of clinical benefit with lazertinib and JNJ-61186372 combination at RP2CD (Phase 1b expansion cohorts)

  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266